Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

PVP Biologics Scores Support from Takeda for Celiac Disease Treatment



Celiac disease affects one percent of the world’s population, according to estimates made by the Celiac Disease Foundation.

Share this!

January 9, 2017 | by Sarah Hand, M.Sc.

Takeda Pharmaceuticals and PvP Biologics have entered into a global agreement to co-develop an enzyme – called KumaMax – designed to help treat patients with celiac disease. The enzyme, which was developed by the biotech startup, helps break down gluten in the stomach to prevent the allergen from triggering an immune reaction and causing damage to the small intestine.

“Takeda’s GI experience and capabilities are a great fit with our goal of developing a novel oral enzyme therapy to make a meaningful impact on the lives of people with celiac disease,” said Adam Simpson, president and CEO of PvP Biologics. “In addition, the significant non-dilutive financing provided by Takeda will accelerate therapeutic development of KumaMax.”

PvP Biologics has agreed to conduct all required research and development through Phase I clinical trials. Takeda will provide $35 million in financing, with the option to acquire the biotech after reviewing the data.

“This agreement with PvP Biologics reinforces Takeda’s commitment to developing therapeutics targeting celiac disease. KumaMax could address a significant unmet need for celiac patients who try, but are unable to completely avoid gluten exposure in their diets, and thus continue to experience debilitating symptoms,” said Asit Parikh, head of the gastroenterology therapeutic area for Takeda. “We are pleased to be partnering with PvP Biologics, a company whose management team has a proven track record of successfully bringing assets that target chronic inflammatory gastrointestinal diseases through development.”

KumaMax is a recombinant enzyme which is currently in preclinical development. Enzymatically active at the low pH found in the stomach, KumaMax specifically targets the parts of the gluten protein that stimulate an autoimmune response. There is no treatment for celiac patients, aside from completely avoiding the allergen by adhering to a limiting gluten-free diet.

“Celiac disease is a disorder in which the ingestion of even a trace amount of gluten can damage the small intestine,” said Dr. Tadataka "Tachi" Yamada, chairman of PvP Biologics. “In pre-clinical experiments, KumaMax has shown the ability to degrade gluten with sufficient efficiency and effectiveness to indicate its exciting potential as an oral therapy for a disease that impairs the lives of millions.”

KumaMax could provide a fail-safe for celiac patients who inadvertently ingest gluten, by degrading the allergen before it can enter the small intestine. This could reduce the painful symptoms and intestinal damage associated with accidental gluten consumption.

Celiac disease affects one percent of the world’s population, according to estimates made by the Celiac Disease Foundation. Celiac disease can progress with exposure to gluten, causing gastrointestinal discomfort, malnutrition and weakness.

Keywords: Celiac Disease, Gluten, Biotech


Share this with your colleagues!

IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

PTC to Acquire Marathon’s Recently Approved Duchenne Muscular Dystrophy Drug

March 17, 2017 - Amid a drug pricing controversy, PTC Therapeutics has agreed to buy Marathon Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug, Emflaza.

Featured In: Pharmaceutical News

Memphis Meats Produces World’s First Poultry from Animal Cells

March 17, 2017 - Silicon Valley-based food manufacturing company, Memphis Meats, has produced the world’s first “clean poultry” by growing chicken and duck cells outside the animals.

Featured In: Food News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


How to Improve the Speed and Efficiency of Your Clinical Trials

High Performance Computing for High Content Screening - A Case Study

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Treatment of Psoriasis: Improvements Through Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.